What are the indications for capmatinib?

Capmatinib (Capmatinib) is a selective MET inhibitor. Its main indication is the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. Such mutations lead to abnormal activation of the MET signaling pathway, thereby promoting tumor growth and spread. Capmatinib can significantly inhibit the proliferation of tumor cells by inhibiting the MET pathway, and has shown a high objective response rate (ORR) in clinical trials.

According to the approval of the U.S. Food and Drug Administration (FDA), capmatinib is suitable for patients who have not received other treatments and patients who have METexon14 skipping mutations after failure of other treatments. In such patients, capmatinib can be used as an important first-line or later-line treatment option, and its efficacy has been verified in multiple clinical studies.

Although the current main indication of capmatinib is targeting METexon14 skipping mutations, studies have also shown that it may be effective in patients with tumors that have amplification or overexpression of the MET gene. Especially in some patients with MET-amplified NSCLC, capmatinib has shown partial efficacy, but these indications still require further research and regulatory approval.

Capmatinib also shows potential in combination with other targeted drugs, such as with EGFR inhibitors to treat patients with EGFR mutations combined with MET amplification. This combination regimen may provide new treatment options for patients who are resistant to single targeted drugs, and relevant research is currently underway.

Except for lung cancer, METexon14 mutations andMETAmplification has also been found in other types of solid tumors, including gastric cancer, liver cancer, and glioblastoma. Although capmatinib's efficacy in these cancers has not been widely proven, there are some preliminary studies suggesting it may have a therapeutic role in other tumor types with abnormal MET.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib